Horowitz Limited Partnership VIII 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Oct 20, 2020
Insider Transaction Report
Form 4
Horowitz Limited Partnership VIII
10% Owner
Transactions
- Purchase
Common Stock
2020-10-20$16.00/sh+168,750$2,700,000→ 1,920,933 total - Conversion
Common Stock
2020-10-20+7,396→ 50,547 total(indirect: By Trust) - Conversion
Series A Preferred Stock
2020-10-20−1,434,790→ 0 total→ Common Stock (1,434,790 underlying) - Conversion
Series B Preferred Stock
2020-10-20−245,966→ 0 total→ Common Stock (245,966 underlying) - Conversion
Series B Preferred Stock
2020-10-20−7,396→ 0 total(indirect: By Trust)→ Common Stock (7,396 underlying) - Conversion
Common Stock
2020-10-20+43,151→ 43,151 total(indirect: By Trust) - Purchase
Common Stock
2020-10-20$16.00/sh+15,625$250,000→ 66,172 total(indirect: By Trust) - Conversion
Series C Preferred Stock
2020-10-20−71,427→ 0 total→ Common Stock (71,427 underlying) - Conversion
Common Stock
2020-10-20+71,427→ 1,752,183 total - Conversion
Series A Preferred Stock
2020-10-20−43,151→ 0 total(indirect: By Trust)→ Common Stock (43,151 underlying) - Conversion
Common Stock
2020-10-20+1,434,790→ 1,434,790 total - Conversion
Common Stock
2020-10-20+245,966→ 1,680,756 total
Footnotes (2)
- [F1]Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.
- [F2]The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.